SHIFT AI Newsroom · GLOBAL
CagriSema Being Compared to Tirzepatide in Type 2 Diabetes Trial
A research study is underway to compare the efficacy of CagriSema and Tirzepatide in lowering blood sugar and body weight in people with type 2 diabetes.
A research study is underway to compare the efficacy of CagriSema and Tirzepatide in lowering blood sugar and body weight in people with type 2 diabetes treated with Metformin, SGLT2 inhibitor or both. The study is registered on ClinicalTrials.gov.
What this means in the UK
The trial's outcome may impact future treatment options for people with type 2 diabetes in the UK.
Known facts
- A research study is comparing the efficacy of CagriSema and Tirzepatide in lowering blood sugar and body weight in people with type 2 diabetes treated with Metformin, SGLT2 inhibitor or both.